1
|
Ho JSS, Ping TL, Paudel KR, El Sherkawi T, De Rubis G, Yeung S, Hansbro PM, Oliver BGG, Chellappan DK, Sin KP, Dua K. Exploring Bioactive Phytomedicines for Advancing Pulmonary Infection Management: Insights and Future Prospects. Phytother Res 2024; 38:5840-5872. [PMID: 39385504 PMCID: PMC11634825 DOI: 10.1002/ptr.8334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2024] [Revised: 07/03/2024] [Accepted: 07/12/2024] [Indexed: 10/12/2024]
Abstract
Pulmonary infections have a profound influence on global mortality rates. Medicinal plants offer a promising approach to address this challenge, providing nontoxic alternatives with higher levels of public acceptance and compliance, particularly in regions where access to conventional medications or diagnostic resources may be limited. Understanding the pathophysiology of viruses and bacteria enables researchers to identify biomarkers essential for triggering diseases. This knowledge allows the discovery of biological molecules capable of either preventing or alleviating symptoms associated with these infections. In this review, medicinal plants that have an effect on COVID-19, influenza A, bacterial and viral pneumonia, and tuberculosis are discussed. Drug delivery has been briefly discussed as well. It examines the effect of bioactive constituents of these plants and synthesizes findings from in vitro, in vivo, and clinical studies conducted over the past decade. In conclusion, many medicinal plants can be used to treat pulmonary infections, but further in-depth studies are needed as most of the current studies are only at preliminary stages. Extensive investigation and clinical studies are warranted to fully elucidate their mechanisms of action and optimize their use in clinical practice.
Collapse
Affiliation(s)
- Joyce Siaw Syuen Ho
- Department of Pharmaceutical Chemistry, School of PharmacyInternational Medical UniversityKuala LumpurMalaysia
| | - Teh Li Ping
- Department of Pharmaceutical Chemistry, School of PharmacyInternational Medical UniversityKuala LumpurMalaysia
| | - Keshav Raj Paudel
- Centre for Inflammation, School of Life Sciences, Faculty of ScienceCentenary Institute and the University of Technology SydneySydneyAustralia
| | - Tammam El Sherkawi
- Discipline of Pharmacy, Graduate School of HealthUniversity of Technology SydneySydneyAustralia
| | - Gabriele De Rubis
- Discipline of Pharmacy, Graduate School of HealthUniversity of Technology SydneySydneyAustralia
- Australian Research Centre in Complementary and Integrative Medicine, Faculty of HealthUniversity of Technology SydneyUltimoAustralia
| | - Stewart Yeung
- Discipline of Pharmacy, Graduate School of HealthUniversity of Technology SydneySydneyAustralia
| | - Philip M. Hansbro
- Centre for Inflammation, School of Life Sciences, Faculty of ScienceCentenary Institute and the University of Technology SydneySydneyAustralia
| | - Brian Gregory George Oliver
- School of Life ScienceUniversity of Technology SydneyUltimoAustralia
- Woolcock Institute of Medical ResearchMacquarie UniversitySydneyAustralia
| | - Dinesh Kumar Chellappan
- Department of Life Sciences, School of PharmacyInternational Medical UniversityKuala LumpurMalaysia
| | - Keng Pei Sin
- Department of Pharmaceutical Chemistry, School of PharmacyInternational Medical UniversityKuala LumpurMalaysia
| | - Kamal Dua
- Discipline of Pharmacy, Graduate School of HealthUniversity of Technology SydneySydneyAustralia
- Australian Research Centre in Complementary and Integrative Medicine, Faculty of HealthUniversity of Technology SydneyUltimoAustralia
| |
Collapse
|
2
|
Bilosomes as Nanoplatform for Oral Delivery and Modulated In Vivo Antimicrobial Activity of Lycopene. Pharmaceuticals (Basel) 2022; 15:ph15091043. [PMID: 36145264 PMCID: PMC9505130 DOI: 10.3390/ph15091043] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Revised: 08/18/2022] [Accepted: 08/22/2022] [Indexed: 01/19/2023] Open
Abstract
Owing to the disseminating resistance among pathogenic bacteria, especially Klebsiella pneumoniae, there is a high need for alternate compounds with antibacterial activity. Herein, lycopene was isolated from Lycopersicon esculentum L. Molecular docking approach was employed to explore lycopene binding affinity to selected vital proteins of K. pneumoniae with the binding mechanisms being investigated. This proposed a promising antibacterial activity of lycopene. However, the pharmacological use of lycopene is hampered by its poor solubility and limited oral bioavailability. Accordingly, bilosomes were fabricated for oral lycopene delivery. The computed entrapment efficiency, mean vesicular size, and zeta potential values for the optimized formulation were 93.2 ± 0.6%, 485.8 ± 35.3 nm, and −38.3 ± 4, respectively. In vitro drug release studies revealed controlled lycopene release from constructed bilosomes, with the drug liberation being based on the Higuchi kinetics model. Transmission electron microscopic evaluation of bilosomes revealed spherical nanovesicles free from aggregates. Moreover, the in vitro and in vivo antibacterial activity of lycopene and its constructed formulations against multidrug-resistant K. pneumoniae isolates were explored. The optimized bilosomes exhibited the lowest minimum inhibitory concentrations ranging from 8 to 32 µg/mL. In addition, scanning electron microscopy revealed remarkable deformation and lysis of the bilosomes-treated bacterial cells. Regarding in vivo investigation, a lung infection model in mice was employed. The tested bilosomes reduced the inflammation and congestion in the treated mice’s lung tissues, resulting in normal-sized bronchioles and alveoli with very few congested vessels. In addition, it resulted in a significant reduction in pulmonary fibrosis. In conclusion, this study investigated the potential activity of the naturally isolated lycopene in controlling infections triggered by multidrug-resistant K. pneumoniae isolates. Furthermore, it introduced bilosomes as a promising biocompatible nanocarrier for modulation of oral lycopene delivery and in vivo antimicrobial activity.
Collapse
|
3
|
Capsanthin induces death in human prostate cancer cell lines by inducing DNA damage. THE EUROBIOTECH JOURNAL 2022. [DOI: 10.2478/ebtj-2022-0010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
There is a relationship between a person’s diet and the development and prevention of some cancers. Carotenoids are found as various natural pigments in many fruits and vegetables. Studies on carotenoids and their potential roles in carcinogenesis are increasing in importance day by day. In this study, we aimed to determine the cytotoxic and genotoxic effects of capsanthin, a carotenoid compound, in human prostate cancer cell lines.
After different concentrations of capsanthin were applied to human prostate cancer cell lines (LNCaP and PC-3), the effects of the compound on cell viability were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. The single-cell gel electrophoresis (Comet) assay was then used to reveal the genotoxic effects of probable cytotoxic dosages on cell DNA. After the treatments, apoptotic cell death levels were determined by Tunel staining. At high concentrations, capsanthin dramatically reduced PC-3 and LNCaP cell viability (p<0.05). In addition, capsanthin caused DNA damage and apoptotic cell death in the prostate cancer cells. The results show that capsanthin reduces cell viability by causing genotoxicity in prostate cancer cells.
Collapse
|
4
|
Tang C, Li Q, Lin T. Lycopene attenuates Staphylococcus aureus-induced inflammation via inhibiting α-Hemolysin expression. Microbes Infect 2021; 23:104853. [PMID: 34224857 DOI: 10.1016/j.micinf.2021.104853] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2021] [Revised: 06/06/2021] [Accepted: 06/09/2021] [Indexed: 01/21/2023]
Abstract
The purpose of this study was to explore the effect of Lycopene in Staphylococcus aureus (S. aureus) (USA 300)-induced inflammation and to elucidate the potential mechanism of its action. The direct effect of Lycopene on S. aureus USA300 growth was determined via growth curves assay, and α-Hemolysin (Hla) release of S. aureus USA300 using hemolysis assay. Furthermore, S. aureus USA300 infected mouse model was established by intranasally infection using bacterial suspension. Histological evaluation of lung tissue after infection was carried out using H&E staining. The lungs edema was estimated using wet/dry ratio. The concentrations of cytokines in lung tissues homogenate were detected using the commercial enzyme-linked immunosorbent assay kit. It was shown that Lycopene inhibited Hla hemolytic activity and decreased expression of Hla and regulatory RNAIII Lycopene treatment protected A549 cells from S. aureus USA300 induced injury and acute lung inflammation. Inflammatory cytokines were also down-regulated by Lycopene treatment in the lung tissues of S. aureus USA300 infected mice. In conclusion, Lycopene restrains S. aureus-induced inflammation via inhibiting α-Hemolysin expression.
Collapse
Affiliation(s)
- Chaogui Tang
- Department of Clinical Laboratory, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, No. 1 Huanghe Road West, Huai'an 223300, Jiangsu, China
| | - Qianhui Li
- Department of Clinical Laboratory, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, No. 1 Huanghe Road West, Huai'an 223300, Jiangsu, China
| | - Tao Lin
- Department of Clinical Laboratory, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, No. 1 Huanghe Road West, Huai'an 223300, Jiangsu, China.
| |
Collapse
|
5
|
Maghsoudi S, Taghavi Shahraki B, Rabiee N, Fatahi Y, Bagherzadeh M, Dinarvand R, Ahmadi S, Rabiee M, Tahriri M, Hamblin MR, Tayebi L, Webster TJ. The colorful world of carotenoids: a profound insight on therapeutics and recent trends in nano delivery systems. Crit Rev Food Sci Nutr 2021; 62:3658-3697. [PMID: 33399020 DOI: 10.1080/10408398.2020.1867958] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The therapeutic effects of carotenoids as dietary supplements to control or even treat some specific diseases including diabetic retinopathy, cardiovascular diseases, bacterial infections, as well as breast, prostate, and skin cancer are discussed in this review and also thoughts on future research for their widespread use are emphasized. From the stability standpoint, carotenoids have low bioavailability and bioaccessibility owing to their poor water solubility, deterioration in the presence of environmental stresses such as oxygen, light, and high heat as well as rapid degradation during digestion. Nanoencapsulation technologies as wall or encapsulation materials have been increasingly used for improving food product functionality. Nanoencapsulation is a versatile process employed for the protection, entrapment, and the delivery of food bioactive products including carotenoids from diverse environmental conditions for extended shelf lives and for providing controlled release. Therefore, we present here, recent (mostly during the last five years) nanoencapsulation methods of carotenoids with various nanocarriers. To us, this review can be considered as the first highlighting not only the potential therapeutic effects of carotenoids on various diseases but also their most effective nanodelivery systems.HighlightsBioactive compounds are of deep interest to improve food properties.Carotenoids (such as β-carotene and xanthophylls) play indispensable roles in maintaining human health and well-being.A substantial research effort has been carried out on developing beneficial nanodelivery systems for various carotenoids.Nanoencapsulation of carotenoids can enhance their functional properties.Stable nanoencapsulated carotenoids could be utilized in food products.
Collapse
Affiliation(s)
- Saeid Maghsoudi
- Department of Medicinal Chemistry, Shiraz University of Technology, Shiraz, Iran
| | | | - Navid Rabiee
- Department of Chemistry, Sharif University of Technology, Tehran, Iran
| | - Yousef Fatahi
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.,Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.,Universal Scientific Education and Research Network (USERN), Tehran, Iran
| | | | - Rassoul Dinarvand
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.,Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Sepideh Ahmadi
- Student Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.,Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mohammad Rabiee
- Biomaterial Group, Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran
| | | | - Michael R Hamblin
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA.,Department of Dermatology, Harvard Medical School, Boston, USA
| | - Lobat Tayebi
- Department of Engineering, Norfolk State University, Norfolk, VA, USA
| | - Thomas J Webster
- Department of Chemical Engineering, Northeastern University, Boston, MA, USA
| |
Collapse
|
6
|
Abstract
PURPOSE OF REVIEW Recent studies regarding the frequency of Chlamydia-induced reactive arthritis (ReA) are reviewed, with a focus on the question of whether the entity is in fact disappearing or whether it is simply being underdiagnosed/underreported. Epidemiological reports indicate diversity in the frequency of Chlamydia-associated ReA in various parts of the world, with evidence of declining incidence in some regions. RECENT FINDINGS The hypothesis that early effective treatment with antibiotics prevents the manifestation of Chlamydia-associated ReA requires further investigation. For clinicians, it is important to remember that ReA secondary to Lymphogranuloma venereum (LGV) serovars L1-L3 of C. trachomatis is probably underestimated due to a limited awareness of this condition, the re-emergence in Western countries of LGV overall, and the present increasingly rare classical inguinal presentation.
Collapse
|
7
|
Prebiotic Effect of Lycopene and Dark Chocolate on Gut Microbiome with Systemic Changes in Liver Metabolism, Skeletal Muscles and Skin in Moderately Obese Persons. BIOMED RESEARCH INTERNATIONAL 2019; 2019:4625279. [PMID: 31317029 PMCID: PMC6604498 DOI: 10.1155/2019/4625279] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 04/01/2019] [Accepted: 04/18/2019] [Indexed: 12/15/2022]
Abstract
Lycopene rich food and dark chocolate are among the best-documented products with a broad health benefit. This study explored the systemic effect of lycopene and dark chocolate (DC) on gut microbiota, blood, liver metabolism, skeletal muscle tissue oxygenation and skin. 30 volunteers were recruited for this trial, 15 women and 15 men with a mean age of 55 ± 5.7 years and with moderate obesity, 30 < BMI < 35 kg/m2. They were randomized and divided into five equal interventional groups: three received different formulations of lycopene, one of them with a 7 mg daily dose and two with 30 mg; another group was given 10 g of DC with 7 mg lycopene embedded into its matrix, and the last group received 10 g DC. The trial was double-blinded for the three lycopene groups and separately for the 2 DC groups; the trial lasted for 1 month. By the end of the trial there were dose-dependent changes in the gut microbiota profile in all three lycopene groups with an increase of relative abundance of, e.g., Bifidobacterium adolescentis and Bifidobacterium longum. This was also accompanied by dose-dependent changes in the blood, liver metabolism, skeletal muscle and skin parameters. Consumption of DC resulted in increased relative abundance of, e.g., Lactobacillus and a reduction of corneocyte exfoliation. This is the first study which reports the prebiotic potential of lycopene and DC.
Collapse
|
8
|
Petyaev IM, Dovgalevsky PY, Klochkov VA, Chalyk NE, Pristensky DV, Chernyshova MP, Udumyan R, Kocharyan T, Kyle NH, Lozbiakova MV, Bashmakov YK. Effect of lycopene supplementation on cardiovascular parameters and markers of inflammation and oxidation in patients with coronary vascular disease. Food Sci Nutr 2018; 6:1770-1777. [PMID: 30258622 PMCID: PMC6145244 DOI: 10.1002/fsn3.734] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Revised: 01/23/2018] [Accepted: 06/08/2018] [Indexed: 02/06/2023] Open
Abstract
Oxidative stress and antioxidant deficiency play a pivotal role in initiation, development, and outcomes of cardiovascular disease. Pharmacokinetic parameters as well as the impact of highly bioavailable lycopene on cardiovascular variables, markers of inflammation and oxidation were investigated during a 30-day clinical trial in patients with coronary vascular disease. The patients were randomized into two major groups and were supplemented with a single 7 mg daily dose of lycopene ingested either in the form of lactolycopene (68 patients) or in the form of lycosome-formulated GA lycopene (74 patients). The endpoints included cardiovascular function parameters, serum lipids, and four markers of oxidative stress and inflammation. Ingestion of lycosome-formulated lycopene increased serum lycopene levels by 2.9- and 4.3-fold, respectively, after 2 and 4 weeks of the trial, whereas supplementation with lactolycopene upregulated serum lycopene by half-fold only after 4 weeks of ingestion. Lycosome formulation of lycopene resulted by the end of the trial in a threefold reduction in Chlamydia pneumoniae IgG and reduction to the same degree of the inflammatory oxidative damage marker. The decrease in oxidized LDL caused by lycosome-formulated lycopene was fivefold. Moreover, supplementation with lycosome-formulated lycopene was accompanied by a significant increase in tissue oxygenation and flow-mediated dilation by the end of the observational period. In contrast, lactolycopene did not cause any significant changes in the parameters studied. Therefore, enhanced bioavailability of lycopene promotes its antioxidant and anti-inflammatory functions and endorses a positive effect of lycopene on cardiovascular system.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Ruzan Udumyan
- Orebro University Hospital and School of Health and Medical SciencesOrebro UniversityÖrebroSweden
| | - Taron Kocharyan
- Orebro University Hospital and School of Health and Medical SciencesOrebro UniversityÖrebroSweden
| | | | | | | |
Collapse
|
9
|
Ejike DE, Adam MA, Sheu OS, Nganda P, Iliya E, Moses DA, Alfred OO, Karimah. Lycopene attenuates diabetes-induced oxidative stress in Wistar rats. ACTA ACUST UNITED AC 2018. [DOI: 10.5897/jde2018.0118] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|